Indazole–Quinolone Hybrids as Anti-Virulence Agents against Pseudomonas aeruginosa - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Drugs and Drug Candidates Année : 2024

Indazole–Quinolone Hybrids as Anti-Virulence Agents against Pseudomonas aeruginosa

Résumé

Antibiotic resistance is a critical public health issue. Among the multi-drug resistant microorganisms in question, Pseudomonas aeruginosa has been designated by the WHO as a priority threat. Its virulence is orchestrated through quorum sensing (QS). This sophisticated communication network relies on the release and perception of autoinducers acting as population density indicators. Therefore, the interest of a quorum silencing pharmacological approach has unfolded to quench bacterial pathogenicity without impairing growth. In this article, we reported the development of a family of indazole–quinolone hybrids as anti-virulence agents. These new biaromatic compounds were designed as potential specific QS quenchers against P. aeruginosa. Our transdisciplinary research methodology included their synthesis using palladocatalyzed cross-coupling reactions, as well as their in silico physicochemical and in vitro biological evaluation. The hit 7-chloro-2-indazolyl-4-quinolone Ie shows a promising anti-biofilm and anti-pyocyanin efficiency (35% inhibition at 25 µM and 35% inhibition at 100 µM, respectively) without an anti-pseudomonal bacteriostatic effect. It also demonstrated a moderate eukaryotic cytotoxicity. Its anti-QS properties have been investigated using metabolomic and molecular modelling studies.

Dates et versions

hal-04660432 , version 1 (23-07-2024)

Identifiants

Citer

Marie Hanot, Marine Duplantier, Céline Dalle, Yani Ren, Sophie Da Nascimento, et al.. Indazole–Quinolone Hybrids as Anti-Virulence Agents against Pseudomonas aeruginosa. Drugs and Drug Candidates, 2024, 3 (3), pp.512-536. ⟨10.3390/ddc3030030⟩. ⟨hal-04660432⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More